然而，研究人员和制药商却大幅削减了用于对新药剂进行评价和临床试验的资金。
However, researchers and pharmaceutical manufacturers have significantly cut back on funds for the evaluation and clinical testing of new agents.
大型制药厂商将受益于此，因为它们所拥有营销机器和大量技术型销售人员能说服医生针对一种药品开出处方。
The big drugs companies will benefit from that because they have marketing machines and large technical sales forces to persuade doctors to prescribe a drug.
研究人员将这一组与其他两组(仍然使用免疫抑制药物并具有健康肾脏的受者，以及健康非移植对照组)进行了比较。
The researchers compared this group with two other groups: recipients who were still taking their immunosuppressive medication and had healthy kidneys, and healthy, non-transplant controls.
应用推荐